Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 124Lymphoma 71Lymphoma, Non-Hodgkin 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Leukemia, Myeloid, Acute 52Myelodysplastic Syndromes 50Neoplasms, Plasma Cell 48Hodgkin Disease 48Leukemia 42Leukemia, Lymphocytic, Chronic, B-Cell 40Lymphoma, Mantle-Cell 35Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Follicular 33Burkitt Lymphoma 24Lymphoma, B-Cell, Marginal Zone 22Lymphoma, Large-Cell, Immunoblastic 21Leukemia, Myelogenous, Chronic, BCR-ABL Positive 21Myeloproliferative Disorders 20Recurrence 19Hematologic Neoplasms 19Immunoglobulin Light-chain Amyloidosis 18Leukemia, Myelomonocytic, Chronic 16Neuroblastoma 15Leukemia, Myeloid, Chronic-Phase 15Leukemia, Myeloid, Accelerated Phase 15Graft vs Host Disease 15Dendritic Cell Sarcoma, Interdigitating 15Anemia, Refractory, with Excess of Blasts 14Waldenstrom Macroglobulinemia 12Primary Myelofibrosis 12

Interventions

XENP 1595 2Dexamethasone 2pomalidomide 1fasudil 1birtamimab 1Melphalan 1Calcium Dobesilate 1Bortezomib 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Alzheimer Disease × Melphalan × Clear all
NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Boston Medical Center

Phase 2 Completed
35 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡